ReviewFrontiers in pharmacology2020
Gender Differences in Cardiovascular Pharmacotherapy-the Example of Hypertension: A Mini Review.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Risk factors for acute kidney injury in Chinese patients with lupus nephritis: a meta-analysis.BMC nephrology · 2026Pooled it
- Pharmacokinetic Variability of Amlodipine Serum Concentration and Effect on Blood Pressure in Patients Treated for Hypertension.Pharmacology research & perspectives · 2025Trial
- Review
- Metabolic Disturbances Associated with Beta-Blocker Therapy: New Insights from a Large-Scale Pharmacovigilance Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Long-term intake of statins or renin-angiotensin system inhibitors: associations with sarcopenia-related parameters in older people.GeroScience · 2026Article
- Frailty and sex differences in blood pressure control in older adults.Scientific reports · 2026Article
- Review
- Gender- and sex-dependent variations in heart failure and cardiomyopathies: a review of the literature.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Sex stratified analysis of patients with resistant hypertension from the Global SYMPLICITY Registry of renal denervation.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- ACE Inhibitors Boost Mobility and Muscle Strength by Reducing Intestinal Permeability in Older Adults with Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Interplay between circadian rhythms, gut microbiota, and MASLD: from mechanistic foundations to therapeutic opportunities.Frontiers in medicine · 2026Review
- Trends in the prevalence of apparent treatment-resistant hypertension among U.S. adults, 1999-2018.American journal of preventive cardiology · 2025Article
- Sex Hormone Androgen Elevates Blood Pressure Through Gut Microbiota-TMAO Pathway.Hypertension (Dallas, Tex. : 1979) · 2025Article
- Sex differences in the prescription of antihypertensive medications in primary care patients: an observational study.BJGP open · 2025Article
- Sex-specific human electromechanical multiscale in-silico models for virtual therapy evaluation.Journal of molecular and cellular cardiology plus · 2025Article
- The impact of sex on blood pressure.Current opinion in nephrology and hypertension · 2025Review
- The Particularities of Arterial Hypertension in Female Sex: From Pathophysiology to Therapeutic Management.Journal of clinical medicine · 2025Review
- Association of migraine treatments with reduced ischemic stroke risk: Evidence from two large-scale real-world data analyses.Headache · 2025Article
- Article
- Differences in sex and age response to single pill combination based antihypertensive therapy reflecting in blood pressure and arterial stiffness.Journal of hypertension · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) is the leading cause of mortality worldwide in both sexes. Despite considerable progress in better understanding the patterns of disease in women, they are still often undertreated and benefit less from evidence-based treatment. Hypertension is a key contributor to CVD and is also one of the most potent risk factors for heart failure in women. Even with the wide variety of available drugs, blood pressure control is globally suboptimal. Current guidelines do not suggest differential treatment of hypertension for women; however, a growing body of research suggests gender dimorphism in the pathophysiology of hypertension and pharmacological response to cardiovascular drugs. The clinical relevance of theses sex-divergent effects of drugs is still under investigation. Owing to the exponential relationship between blood pressure and cardiovascular mortality, even a modest decrease in blood pressure or therapeutic adhesion could be clinically \relevant. In this review, we explore the known pharmacological and pharmacokinetic sex differences with special attention to the main classes of antihypertensive treatment. Current data shows frequently higher drug exposures in women and more frequent adverse drug reactions in all antihypertensive drug groups. As far as cardiovascular prevention is concerned, sex-specific data is often lacking in clinical trials, highlighting the necessity to further study CVD and their treatment in both men and women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.